CytRx's (CYTR) Tamibarotene Receives Positive Opinion from the Committee for Orphan Medicinal Products in the EU for Treatment of APL
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR) announced that its lead drug candidate tamibarotene has received official notification from the Committee for Orphan ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
